glp1InjectableNot FDA-approvedPrescription only (US)Not yet FDA- or EMA-approved; the registrational TRIUMPH phase 3 program was ongoing as of the cited design paperCurrently available to patients only as a trial participant, not as a prescribed or over-the-counter product
Retatrutide (LY3437943)Benefits, Dosage & Interactions
Also known as: Retatrutide
Retatrutide (LY3437943) is an investigational unimolecular peptide that acts as an agonist at three distinct receptors: the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. Research on Retatrutide (LY3437943) focuses on weight loss, blood sugar control, and heart and circulatory health.
Researched by DoseRoutine R&D TeamReviewed for accuracy by Nicholas Alexander, RSELast updated
Evidence: Strong — 2 human randomized trials published.
Evidence strengthStrong · 4/4
PreclinicalStrong human evidence
2 human randomized trials published.
Plasma half-life
~6 days
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- The phase 2 obesity trial titrated to maintenance doses of 1, 4, 8, or 12 mg once weekly; the phase 2 type 2 diabetes trial used a similar titrated once-weekly dosing range[1][2]
Reported for Retatrutide (LY3437943) in the cited sources. Published ranges are not dosing advice.
References & evidence
Documents the Retatrutide (LY3437943) entry is written from. Each number matches an inline marker above.
- [1]Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 TrialJastreboff AM, Kaplan LM, Frías JP, et al. · The New England Journal of Medicine · 2023 · Peer-reviewed · PMID 37366315
- [2]Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USARosenstock J, Frías J, Jastreboff AM, et al. · Lancet · 2023 · Peer-reviewed · PMID 37385280
- [3]Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trialsGiblin K, et al. · Diabetes, Obesity & Metabolism · 2026 · Peer-reviewed · PMID 41090431
How to track Retatrutide (LY3437943) doses
Retatrutide (LY3437943) is tracked as a protocol rather than a single reminder: a vial with a concentration, a schedule that may be titrated or cycled, and a rotation of injection sites. Here is the record that keeps all three consistent.
- 1
Record the vial and concentration
Log the vial strength and the volume of bacteriostatic water you added so Retatrutide (LY3437943) is stored as a concentration rather than a guess. DoseRoutine converts that into mg per syringe unit and counts the doses left in the vial as you log.
- 2
Set the schedule, not just a reminder
Enter the dose in mg and the frequency. Cycled protocols get a start and end date so the history stays accurate when Retatrutide (LY3437943) comes out of the routine.
- 3
Rotate and log the injection site
Pick the site at the moment you log the dose. The site map shows what you used last and how recently, which is the part that drifts fastest when two compounds run on different frequencies.
- 4
Log adherence, not intentions
Mark each dose taken, skipped or delayed as it happens. Weeks of honest logs are what make an adherence rate or a trend line meaningful; retrospective guessing is not.
- 5
Review against outcomes
With a reported half-life around 144 h, effects and timing shifts show up over days rather than instantly. Review Retatrutide (LY3437943) alongside your logged metrics and any relevant blood work every few weeks before changing the dose.
What to log each time
- Dose in mg and the syringe units it worked out to
- Vial: reconstitution date, concentration, doses remaining
- Injection site and time
- Any side effects in the 24 h after the dose
References & Evidence
Sources on this page that document Retatrutide (LY3437943) dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Retatrutide (LY3437943) studied for?
What is Retatrutide (LY3437943)?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Retatrutide (LY3437943) is an investigational unimolecular peptide that acts as an agonist at three distinct receptors: the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triple agonism distinguishes it from other incretin-based therapies that typically target one or two of these pathways. Developed by Eli Lilly and Company, Retatrutide is currently undergoing clinical trials primarily for the treatment of obesity and related metabolic conditions, including type 2 diabetes. Its unique multimodal action is hypothesized to lead to enhanced effects on body weight reduction and glycemic control compared to single- or dual-agonist approaches. Clinical studies have explored its efficacy and safety profile across various populations, aiming to establish its potential role in managing chronic metabolic diseases. As an injectable peptide, its administration is typically subcutaneous. Information regarding Retatrutide is primarily derived from clinical trial reports and scientific publications, as it is not yet approved for clinical use (Eli Lilly Clinical Trials, scientific literature).
What does the research say about Retatrutide (LY3437943)?
Tap a section to expand.
Retatrutide functions as an agonist simultaneously binding to and activating three G protein-coupled receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This multi-targeted approach aims to leverage the distinct physiological roles of these incretin hormones and glucagon in regulating metabolism.
Activation of the GLP-1 receptor leads to several well-established effects, including enhanced glucose-dependent insulin secretion from pancreatic beta cells, suppression of glucagon secretion from pancreatic alpha cells, delayed gastric emptying, and increased satiety, all contributing to improved glycemic control and reduced food intake (PubChem, DrugBank).
Stimulation of the GIP receptor also promotes glucose-dependent insulin secretion and may contribute to beta-cell preservation. GIP's role in weight regulation is complex, with some studies suggesting a pro-adipogenic effect, while others indicate its importance in overall metabolic homeostasis (PubChem, DrugBank).
Agonism at the glucagon receptor is a unique feature of Retatrutide among incretin mimetics. While glucagon is typically associated with increasing blood glucose, its agonism in the context of Retatrutide is hypothesized to induce energy expenditure, increase resting metabolic rate, and potentially promote lipolysis (fat breakdown) in adipose tissue. This action, combined with GLP-1 and GIP signaling, is thought to contribute to more pronounced weight loss compared to agents targeting only GLP-1 or GLP-1/GIP (Eli Lilly Clinical Trials presentations, scientific literature).
The integrated action of these three pathways aims to regulate appetite, enhance satiety, improve glucose metabolism, and increase energy expenditure, thereby leading to substantial reductions in body weight and improvements in metabolic parameters.
Source for this section: Sources for How does Retatrutide (LY3437943) work?: Jumps to this entry in the sources and references list at the end of the page.
Clinical trials of Retatrutide have primarily investigated its potential benefits in two major areas: significant body weight reduction and improved glycemic control, particularly in individuals with obesity and/or type 2 diabetes. Its triple-agonist mechanism is hypothesized to confer advantages over single or dual incretin-based therapies.
* **Body Weight Reduction:** Early phase clinical trials have demonstrated substantial dose-dependent body weight loss in individuals with obesity or overweight, with reported mean reductions exceeding those typically observed with GLP-1 receptor agonists or GLP-1/GIP co-agonists (Eli Lilly Clinical Trials, scientific publications). This effect is thought to be mediated by a combination of reduced appetite, increased satiety, delayed gastric emptying, and potentially increased energy expenditure due to glucagon receptor agonism.
* **Glycemic Control:** In individuals with type 2 diabetes, Retatrutide has shown promising results in lowering glycated hemoglobin (HbA1c) and fasting plasma glucose levels. This improvement in glycemic control is attributed to enhanced glucose-dependent insulin secretion, suppressed glucagon secretion, and potentially improved insulin sensitivity (Eli Lilly Clinical Trials, scientific publications).
* **Metabolic Improvements:** Beyond weight and glucose, studies have also indicated potential benefits in other metabolic parameters, such as reductions in lipid profiles (e.g., triglycerides, LDL cholesterol) and improvements in blood pressure. These improvements are often secondary to significant weight loss and better glycemic control (scientific literature).
* **Appetite and Satiety Regulation:** Patients receiving Retatrutide often report reduced hunger and increased feelings of fullness, which are key mechanisms contributing to decreased caloric intake and subsequent weight loss (clinical trial participant reports).
It is important to note that these benefits are based on ongoing clinical trials, and the full spectrum of advantages will be clarified upon completion of larger, longer-term studies and potential regulatory approval.
Evidence for Retatrutide's efficacy and safety is primarily derived from ongoing phase 1, phase 2, and phase 3 clinical trials sponsored by Eli Lilly and Company, as well as peer-reviewed scientific publications reporting on these trials. As an investigational compound, data are continuously emerging.
**Phase 2 Trial Data:** A notable randomized, double-blind, placebo-controlled phase 2 study investigated the efficacy and safety of Retatrutide in adults with obesity or overweight. The study demonstrated significant, dose-dependent reductions in body weight over several months. For instance, participants receiving higher doses of Retatrutide experienced mean weight reductions considerably greater than those on placebo, with a substantial proportion achieving a 15% or greater weight loss (published clinical trial data, scientific journals). The study also reported improvements in various cardiometabolic risk factors.
**Mechanism-Based Evidence:** Preclinical studies and early human data support the hypothesized triple-agonist mechanism, showing activation of GLP-1, GIP, and glucagon receptors and their downstream effects on insulin secretion, glucagon suppression, and energy expenditure (scientific publications, Eli Lilly presentations).
**Ongoing Trials:** A comprehensive phase 3 clinical development program, known as the TRANSLATE program, is currently underway. These trials are designed to evaluate Retatrutide's long-term efficacy and safety for chronic weight management and in individuals with type 2 diabetes and obesity. Data from these large-scale trials will provide definitive evidence for its potential role in clinical practice (Eli Lilly Clinical Trials website).
It is critical to remember that while promising, these results are from clinical research settings. Further robust evidence from completed phase 3 trials and post-marketing surveillance will be essential to fully characterize its benefits and risks in broader populations.
As with any medication, Retatrutide is associated with potential side effects, which have been observed during clinical trials. The most commonly reported side effects typically involve the gastrointestinal system, similar to other incretin-based therapies, but may vary in frequency and severity given Retatrutide's triple-agonist mechanism.
* **Gastrointestinal Effects:** These are frequently reported and include nausea, vomiting, diarrhea, and constipation. These symptoms are often dose-dependent and tend to be more prevalent during treatment initiation or dose escalation, often resolving or improving over time as the body adjusts (clinical trial reports, scientific literature).
* **Abdominal Pain:** Some individuals may experience abdominal discomfort or pain.
* **Decreased Appetite:** While often a desired therapeutic effect contributing to weight loss, a significantly decreased appetite could be considered a side effect if it leads to inadequate nutritional intake or discomfort.
* **Injection Site Reactions:** As an injectable medication, redness, swelling, or pain at the injection site may occur, though these are typically mild and transient.
* **Hypoglycemia (low blood sugar):** While Retatrutide is glucose-dependent in its insulin-stimulating action, potentially reducing the risk of hypoglycemia compared to sulfonylureas or insulin, hypoglycemia can still occur, especially when used in conjunction with other glucose-lowering agents or if food intake is significantly reduced (clinical trial data).
* **Pancreatitis:** Although rare, some incretin-based therapies have been associated with reports of pancreatitis. Clinical trials of Retatrutide monitor for this potential adverse event (scientific literature).
* **Gallbladder-related issues:** Rapid weight loss, which can be induced by Retatrutide, is a known risk factor for gallstone formation and cholecystitis (inflammation of the gallbladder). This is a consideration for any therapy causing significant weight loss (scientific literature).
The severity and incidence of side effects can vary among individuals. Patients should discuss potential side effects with a healthcare professional. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Before considering Retatrutide, several important warnings and precautions should be understood, based on ongoing clinical data and experience with similar incretin-based medications:
* **Thyroid C-cell Tumors:** In rodent studies, GLP-1 receptor agonists have been associated with an increased risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is unknown whether Retatrutide causes thyroid C-cell tumors, including MTC, in humans. Individuals with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) are typically excluded from trials and should avoid using this class of drugs. Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value in patients treated with GLP-1 receptor agonists (FDA labels for similar drugs).
* **Pancreatitis:** Acute pancreatitis has been observed with GLP-1 receptor agonists. Patients should be monitored for signs and symptoms of pancreatitis, such as persistent severe abdominal pain, sometimes radiating to the back, with or without vomiting. If pancreatitis is suspected, Retatrutide should be discontinued.
* **Gallbladder Disease:** Rapid weight loss, a potential effect of Retatrutide, can increase the risk of cholelithiasis (gallstones) and cholecystitis (inflammation of the gallbladder). Patients should be advised of the symptoms of gallbladder disease.
* **Hypoglycemia:** The risk of hypoglycemia may be increased when Retatrutide is co-administered with insulin secretagogues (e.g., sulfonylureas) or insulin. Dose adjustments of other glucose-lowering medications may be necessary.
* **Renal Impairment:** There have been post-marketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists. Some of these events were reported in patients without known underlying renal disease. A majority of reported events occurred in patients who experienced nausea, vomiting, or diarrhea leading to dehydration. Caution should be exercised in patients with renal impairment (FDA labels for similar drugs).
* **Gastrointestinal Effects:** Severe gastrointestinal adverse reactions (e.g., nausea, vomiting, diarrhea) could lead to dehydration and potentially exacerbate renal impairment.
* **Drug Interactions:** Retatrutide delays gastric emptying, which could affect the absorption of concomitantly administered oral medications. Patients should be monitored for altered effects of co-administered oral drugs (scientific literature).
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Based on the safety profile of similar medications and initial findings from clinical trials, certain conditions may represent contraindications for Retatrutide:
* **History of Medullary Thyroid Carcinoma (MTC):** Retatrutide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), due to the observed risk of thyroid C-cell tumors in rodent studies with GLP-1 receptor agonists (FDA labels for similar drugs).
* **History of Acute Pancreatitis:** While not yet a definitive contraindication, patients with a history of pancreatitis are often excluded from clinical trials and should be considered with caution, given the potential for this class of drugs to exacerbate or induce pancreatitis.
* **Known Hypersensitivity:** Individuals with a known serious hypersensitivity to Retatrutide or any of its excipients are contraindicated from using it. Serious hypersensitivity reactions, such as anaphylaxis or angioedema, have been reported with GLP-1 receptor agonists.
* **Pregnancy:** Given the lack of sufficient data on human pregnancy and potential risks observed in animal reproduction studies with related compounds, Retatrutide is generally contraindicated in pregnant women.
* **Breastfeeding:** It is unknown whether Retatrutide is excreted in human milk. A decision must be made whether to discontinue breastfeeding or to discontinue the drug, considering the importance of the drug to the mother.
* **Severe Renal Impairment/End-Stage Renal Disease:** Caution is advised, and it may be contraindicated in severe cases, particularly if compounded by dehydration from gastrointestinal side effects (FDA labels for similar drugs).
These contraindications are based on current knowledge and the understanding of related medications. Specific guidelines will be established upon regulatory approval. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
As an investigational compound, comprehensive drug interaction data for Retatrutide are still being accumulated. However, based on its mechanism of action and experience with similar compounds, several important interactions or classes of compounds should be considered:
* **Insulin Secretagogues (e.g., Sulfonylureas) or Insulin:** Co-administration with these agents increases the risk of hypoglycemia. Dose adjustments of sulfonylureas or insulin may be necessary when initiating Retatrutide therapy, and patients should be routinely monitored for signs and symptoms of hypoglycemia (FDA labels for similar drugs).
* **Oral Medications with a Narrow Therapeutic Index:** Retatrutide delays gastric emptying, which could potentially affect the absorption rate and extent of concomitantly administered oral medications. Particular caution is advised for drugs that require rapid gastrointestinal absorption or have a narrow therapeutic index (e.g., warfarin, levothyroxine, oral contraceptives). Monitoring for altered drug effects is recommended (scientific literature, FDA labels for similar drugs).
* **Other GLP-1 Receptor Agonists, GIP Analogues, or Glucagon Analogues:** Given that Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors, it is generally not recommended to combine it with other medications that work through these same pathways, due to potential for additive effects on blood sugar, gastrointestinal side effects, and unknown safety implications. Combination therapy is typically studied in carefully controlled clinical trial settings.
* **Herbal Supplements or Over-the-Counter Medications that Affect Blood Glucose:** Any supplement or medication that can impact blood glucose levels (e.g., some diabetes-specific supplements, high-dose niacin) should be used with caution and discussed with a clinician, as they may alter the glycemic effects of Retatrutide.
Patients should always inform their healthcare provider of all prescription medications, over-the-counter drugs, and herbal supplements they are taking to avoid potential adverse interactions. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Retatrutide is administered via subcutaneous injection. Clinical trial methodologies typically specify a consistent administration schedule to maintain therapeutic levels and assess efficacy. The exact timing recommendations for commercial use will be determined upon regulatory approval and based on the final drug label.
* **Frequency:** Based on its reported half-life of approximately 140 hours (Eli Lilly Clinical Trials, scientific presentations), Retatrutide is designed for once-weekly administration.
* **Day of the Week:** Patients are often instructed to administer the injection on the same day each week, at any time of day, without regard to meals. This consistency helps maintain stable drug levels.
* **Missed Doses:** Protocols for missed doses usually involve administering the missed dose as soon as remembered if within a certain window from the regularly scheduled day, and then resuming the once-weekly schedule from that point. If too much time has passed, patients may be advised to skip the missed dose and resume on the next regularly scheduled day to avoid double dosing.
Specific instructions regarding injection sites, storage, and handling will be detailed in the official prescribing information if the drug receives approval. Dosage is user-directed and must be set by a licensed clinician.
Source for this section: Sources for When should you take Retatrutide (LY3437943)?: Jumps to this entry in the sources and references list at the end of the page.
What interacts with Retatrutide (LY3437943)?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any glp1 + supplement | Note | Category ruleConfidence: theoretical | GLP-1 medications slow stomach emptying, changing how/when oral supplements absorb; rapid weight loss raises the importance of protein and micronutrients.Source pending | Time oral supplements when nausea is lowest; prioritize protein and micronutrients; discuss with your provider. |
| Insulin (Rapid) | Caution | Compound pairConfidence: theoretical | Combining a GLP-1 with rapid insulin increases hypoglycemia risk.Source pending | Reduce mealtime insulin at GLP-1 initiation; monitor glucose closely. |
| Insulin (Long-Acting) | Caution | Compound pairConfidence: theoretical | GLP-1 plus basal insulin increases hypoglycemia risk.Source pending | Reduce basal insulin dose 10–20% at GLP-1 initiation and titrate. |
Frequently asked questions about Retatrutide (LY3437943)
Retatrutide (LY3437943) is an investigational drug that acts on three different hormone receptors in the body: GLP-1, GIP, and glucagon receptors. By activating these receptors, it helps regulate appetite, slow digestion, improve blood sugar control, and potentially increase energy expenditure, leading to significant weight loss and improved metabolic health (Eli Lilly Clinical Trials, scientific literature).
No, Retatrutide is currently an investigational drug and is not yet approved by regulatory bodies like the FDA for commercial use. It is undergoing comprehensive clinical trials to evaluate its efficacy and safety (Eli Lilly Clinical Trials).
Clinical trials are primarily investigating Retatrutide’s potential for substantial body weight reduction in people with obesity or overweight, and improved blood sugar control (HbA1c) in individuals with type 2 diabetes. It may also lead to improvements in other cardiovascular risk factors (scientific publications).
The most common side effects observed in clinical trials are gastrointestinal in nature, including nausea, vomiting, diarrhea, and constipation. These are often mild to moderate, especially at the start of treatment, and tend to improve over time (clinical trial reports).
Retatrutide is administered as a subcutaneous injection, typically once weekly. The exact instructions for administration, including injection sites and storage, will be provided in the official prescribing information if the drug receives regulatory approval.
Interaction risk for Retatrutide (LY3437943) comes from the rest of the stack: other supplements, prescription medicines, hormone therapy and peptides. With a reported plasma half-life near 144 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Retatrutide (LY3437943) with no sign-up.
Retatrutide (LY3437943) is administered by injection, so the measured volume — not a tablet count — is the unit that matters. The reported plasma half-life is about 144 hours, which is what drives how often it is redosed. Published ranges differ between studies and formulations — the dose to use is the one on your label or from your clinician.
There is no single answer for Retatrutide (LY3437943) plus TRT. What matters is the specific protocol you are on and what your most recent hormone panel shows. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Pairing Retatrutide (LY3437943) with peptides has to be assessed one peptide at a time, because GLP-1 agonists, secretagogues, healing peptides and melanocortins do not share an interaction profile. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
A long plasma half-life of about 144 hours means Retatrutide (LY3437943) is commonly dosed every few days or weekly rather than daily. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
With a plasma half-life near 144 hours, a single missed dose of Retatrutide (LY3437943) usually has a smaller effect on overall exposure than an irregular pattern of missed doses does. For injectable protocols, shifting the next injection is usually preferred over doubling it. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For an injectable like Retatrutide (LY3437943) the record needs more than a checkbox: vial concentration, the measured volume, and which site the last injection went into. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
Which studies looked at Retatrutide (LY3437943)?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.(opens PubMed in a new tab)Lancet (London, England) · 2022 · PMID 36354040 · https://pubmed.ncbi.nlm.nih.gov/36354040/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 172898051(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/172898051
Verify at
Publisher search links for Retatrutide (LY3437943). These are places to check the information — they are not citations, so they are not numbered.
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- MedlinePlus(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Retatrutide (LY3437943)?
Plain-text summary, safe to quote verbatim:
Retatrutide (LY3437943) is an investigational unimolecular peptide that acts as an agonist at three distinct receptors: the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. Research on Retatrutide (LY3437943) focuses on weight loss, blood sugar control, and heart and circulatory health.
Source: DoseRoutine — https://doseroutine.com/library/retatrutide-ly
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Retatrutide (LY3437943) — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/retatrutide-ly
What compounds are similar to Retatrutide (LY3437943)?
Others in the glp1 category or studied for the same goals.
Which goals is Retatrutide (LY3437943) used for?
Other compounds studied for the same benefits as Retatrutide (LY3437943).
Continue exploring
See every compound DoseRoutine catalogs for these goals.